<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7077973\results\search\drugs\results.xml">
  <result pre="PrEP and PEP.8–10 In 2015, a pilot study of daily" exact="doxycycline" post="as syphilis PrEP in HIV-positive gbMSM in Los Angeles"/>
  <result pre="compared with a contingency management intervention.9,11 Another randomized trial assessed" exact="doxycycline" post="as STI PEP versus no intervention in 232 HIV-negative"/>
  <result pre="doxycycline-based PrEP was lower, at 44.1%. Because the definitions of" exact="doxycycline" post="PEP and PrEP provided to participants only differed in"/>
  <result pre="trial of combined syphilis and HIV PrEP using both daily" exact="doxycycline" post="and tenofovir disoproxil fumarate/emtricitabine, with final results expected in"/>
  <result pre="combined syphilis and HIV PrEP using both daily doxycycline and" exact="tenofovir" post="disoproxil fumarate/emtricitabine, with final results expected in summer/fall 2020.24"/>
  <result pre="affordable drug used in the treatment of many common infections," exact="doxycycline" post="is already publicly covered in both Ontario and British"/>
  <result pre="concept of antimicrobial resistance, this knowledge was not associated with" exact="doxycycline" post="PrEP and PEP acceptability. However, the potential for long-term"/>
  <result pre="doxycycline PrEP and PEP acceptability. However, the potential for long-term" exact="doxycycline" post="use to induce resistance in both normal host flora"/>
  <result pre="a joint policy statement warning that the potential benefit of" exact="doxycycline" post="PEP for STIs would be outweighed by the risk"/>
  <result pre="STI PrEP or PEP have formally evaluated the emergence of" exact="tetracycline" post="class resistance in host normal flora, and the limited"/>
  <result pre="data from Neisseria gonorrhoeae and C. trachomatis isolates in the" exact="doxycycline" post="PEP trial has suggested no increase in resistance or"/>
  <result pre="Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/report-sexually-transmitted-infections-canada-2013-14/report-sexually-transmitted-infections-canada-2013-14-eng.pdf. Accessed December 13, 2018. 4HottesTSLesterRTHoangLMet al.Cephalosporin and" exact="azithromycin" post="susceptibility in Neisseria gonorrhoeae isolates by site of infection,"/>
  <result pre="pilot study. Sex Transm Dis2015; 42:98–103.25585069 10MolinaJMCharreauIChidiacCet al.Post-exposure prophylaxis with" exact="doxycycline" post="to prevent sexually transmitted infections in men who have"/>
  <result pre="gay men. Sex Transm Dis2011; 38:573–579.21343845 20SpinelliMAScottHVittinghoffEet al.High interest in" exact="doxycycline" post="for sexually transmitted infection post-exposure prophylaxis (doxy-PEP) in a"/>
  <result pre="British Association for Sexual Health and HIV. Position statement on" exact="doxycycline" post="as post-exposure prophylaxis for sexually transmitted infections. Available at:"/>
 </snippets>
</snippetsTree>
